Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVRL1 | P37023 | 4/20 | 0.44 |
| ▸ | BRAF | P15056 | 6/20 | 0.44 |
| ▸ | TYK2 | P29597 | 8/20 | 0.42 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | CDK9 | P50750 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24738254 | 0.93 | ACVRL1 (0.44) | ACVRL1BRAFTYK2PIK3C3JAK2 | |
| SCHEMBL24739947 | 0.89 | ACVRL1 (0.40) | ACVRL1BRAFTYK2PIK3C3JAK2 | |
| SCHEMBL29302935 | 0.84 | TYK2 (0.40) | BRAFTYK2 | |
| SCHEMBL24737728 | 0.84 | ACVRL1 (0.48) | ACVRL1BRAFTYK2PIK3C3JAK2 | |
| SCHEMBL24737624 | 0.82 | ACVRL1 (0.42) | ACVRL1BRAFTYK2PIK3C3JAK2 | |
| SCHEMBL29304981 | 0.81 | BRAF (0.39) | ACVRL1BRAFTYK2PIK3C3JAK2 | |
| SCHEMBL29305556 | 0.79 | BRAF (0.37) | ACVRL1BRAFTYK2PIK3C3JAK2 | |
| SCHEMBL29879615 | 0.78 | TYK2 (0.39) | BRAFTYK2 | |
| SCHEMBL24738018 | 0.78 | TYK2 (0.38) | ACVRL1BRAFTYK2 | |
| SCHEMBL29879450 | 0.78 | TYK2 (0.38) | ACVRL1BRAFTYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK5, KLK1 | ACVRL1 3569/4885BRAF 3329/4885TYK2 1836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.